OAM
GMAB icon

Oppenheimer Asset Management’s Genmab GMAB Stock Holding History

Oppenheimer Asset Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.3M Sell
447,426
-10,082
-2% -$268K 0.13% 182
2026
Q1 		$12.3M Buy
457,508
+92,752
+25% +$2.78M 0.14% 173
2025
Q4 		$11.2M Buy
364,756
+48,894
+15% +$1.52M 0.14% 171
2025
Q3 		$9.69M Buy
315,862
+61,311
+24% +$1.49M 0.11% 217
2025
Q2 		$5.26M Buy
254,551
+5,083
+2% +$104K 0.06% 332
2025
Q1 		$4.88M Buy
249,468
+42,361
+20% +$889K 0.06% 318
2024
Q4 		$4.32M Sell
207,107
-25,136
-11% -$552K 0.05% 350
2024
Q3 		$5.66M Buy
232,243
+14,165
+6% +$379K 0.07% 296
2024
Q2 		$5.48M Buy
218,078
+45,376
+26% +$1.29M 0.07% 292
2024
Q1 		$5.17M Sell
172,702
-10,951
-6% -$322K 0.08% 281
2023
Q4 		$5.85M Sell
183,653
-9,708
-5% -$305K 0.08% 277
2023
Q3 		$6.82M Buy
193,361
+3,151
+2% +$120K 0.1% 227
2023
Q2 		$7.23M Buy
190,210
+79,783
+72% +$3.18M 0.11% 222
2023
Q1 		$4.17M Buy
110,427
+455
+0.4% +$17.5K 0.06% 305
2022
Q4 		$4.66M Sell
109,972
-25,753
-19% -$1.06M 0.08% 283
2022
Q3 		$4.36M Sell
135,725
-4,359
-3% -$153K 0.08% 276
2022
Q2 		$4.55M Buy
140,084
+3,228
+2% +$105K 0.08% 270
2022
Q1 		$4.95M Sell
136,856
-25,300
-16% -$868K 0.07% 296
2021
Q4 		$6.42M Sell
162,156
-6,683
-4% -$279K 0.09% 259
2021
Q3 		$7.38M Sell
168,839
-15,142
-8% -$680K 0.1% 222
2021
Q2 		$7.51M Buy
183,981
+7,000
+4% +$270K 0.11% 222
2021
Q1 		$5.81M Buy
176,981
+12,903
+8% +$485K 0.09% 263
2020
Q4 		$6.67M Buy
164,078
+5,284
+3% +$198K 0.11% 213
2020
Q3 		$5.81M Sell
158,794
-30,653
-16% -$1.11M 0.11% 209
2020
Q2 		$6.42M Sell
189,447
-55,225
-23% -$1.5M 0.13% 180
2020
Q1 		$5.18M Buy
244,672
+8,231
+3% +$183K 0.13% 188
2019
Q4 		$5.28M Buy
236,441
+138
+0.1% +$3.01K 0.11% 221
2019
Q3 		$4.79M Buy
+236,303
New +$4.65M 0.11% 228

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Oppenheimer Asset Management's GMAB Position: Q2 2026 in Review

Oppenheimer Asset Management reduced its Genmab (GMAB) stake by 2.2% in Q2 2026, selling an estimated $268K and leaving 447,426 shares worth $12.3M. The position accounts for 0.13% of the portfolio, ranked #182.

Oppenheimer Asset Management first reported a position in GMAB in Q3 2019 and has held it in 28 quarters since. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Oppenheimer Asset Management held 447,426 shares of Genmab worth $12.3M as of Q2 2026.
  • Oppenheimer Asset Management sold 10,082 Genmab shares in Q2 2026, an estimated $268K.
  • Genmab made up 0.13% of Oppenheimer Asset Management's portfolio in Q2 2026, its #182 holding.
  • Oppenheimer Asset Management first reported a position in Genmab in Q3 2019 and has held it in 28 quarters since.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.